Recent Quotes (30 days)

You have no recent quotes
chg | %

Roche Holding Ltd. (ADR)  

(Public, OTCMKTS:RHHBY)   Watch this stock  
Find more results for PINK:RHHBY
27.87
+0.79 (2.92%)
Delayed:   12:15PM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 27.59 - 27.94
52 week 25.25 - 35.13
Open 27.67
Vol / Avg. 716,129.00/1.22M
Mkt cap 192.31B
P/E 21.47
Div/yield 1.02/3.65
EPS 1.30
Shares 692.21M
Beta 0.83
Inst. own 15%
Feb 1, 2017
Full Year 2016 Roche Holding AG Earnings Release - 1:00AM EST - Add to calendar
Jan 9, 2017
Roche Holding AG at JPMorgan Healthcare Conference Add to calendar
Dec 7, 2016
Roche Holding AG at Citi Global Healthcare Conference
Dec 6, 2016
Roche Holding AG at Berenberg European Conference
Dec 5, 2016
Roche Holding AG Analyst Event At ASH 2016
Dec 1, 2016
Roche Holding AG at Evercore ISI MedTools Conference
Dec 1, 2016
Roche Holding AG at Deutsche Bank dbAccess Pharmaceutical and Healthcare Corporate Day
Nov 30, 2016
Roche Holding AG at Societe Generale Premium Review Conference
Nov 22, 2016
Roche Holding AG at Exane SRI Conference
Nov 18, 2016
Roche Holding AG at JPMorgan CEO Conference Call Series
  

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 21.85% 18.81%
Operating margin 32.51% 27.89%
EBITD margin - 40.92%
Return on average assets 14.51% 11.97%
Return on average equity 54.40% 43.70%
Employees 91,747 -
CDP Score - 100 A

Address

Grenzacherstrasse 124
BASEL, 4058
Switzerland
+41-9-732354295 (Phone)

Website links

External links

Description

Roche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai. Its Diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. It develops medicines for the disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its product portfolio consists of Pharmaceuticals, Solutions for Diagnostics and Products for Researchers. Its Pharmaceutical products include ACTEMRA and CellCept. Its Solutions for Diagnostics products include Accu-Chek Active System and Accu-Chek Aviva Nano System. The Company's Products for Researchers include Cedex HiRes and Genome Sequencer FLX System.

Officers and directors

Severin Schwan Chairman of the Corporate Executive Committee, Chief Executive Officer, Director
Age: 49
Alan Hippe Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
Age: 49
Stephan Feldhaus Member of the Enlarged Corporate Executive Committee, Head Group Communications
Age: 54
Sophie Kornowski-Bonnet Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Age: 53
Osamu Nagayama Member of the Enlarged Corporate Executive Committee, President and Chief Executive Officer of Chugai
Age: 69
John C. Reed M.D., Ph.D. Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Age: 58
Michael David Varney Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Age: 58
Urs Jaisli Chief Compliance Officer
Age: 60
Gottlieb A. Keller Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors
Age: 62
Silvia Ayyoubi Member of the Corporate Executive Committee, Head Group Human Resources
Age: 63